Brokers Suggest Investing in CRISPR Therapeutics (CRSP): Read This Before Placing a Bet

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Zacks Investment Research • Oct 21, 2026

CRISPR Therapeutics Announces Chief Financial Officer Transition

ZUG, Switzerland and BOSTON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that its Chief Financial Officer, Raju Prasad, Ph.D., will be stepping down from the Company to pursue external opportunities, and A.J.

GlobeNewsWire • Oct 19, 2026

Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.

CRISPR Therapeutics' shares have declined more than 25% over the past year. The gene-editing biotech has one approved therapy, Casgevy.

The Motley Fool • Oct 18, 2026

Where Will CRISPR Therapeutics Stock Be in 2030?

CRISPR Therapeutics has an approved product on the market that could gain significant commercial traction over the medium term. The company could also make substantial pipeline and regulatory progress.

The Motley Fool • Oct 18, 2026

CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know

CRISPR Therapeutics AG (CRSP) concluded the recent trading session at $49.21, signifying a -4.48% move from its prior day's close.

Zacks Investment Research • Oct 16, 2026

Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock

Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Investment Research • Oct 12, 2026

CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know

CRISPR Therapeutics AG (CRSP) closed at $51.55 in the latest trading session, marking a -3.45% move from the prior day.

Zacks Investment Research • Oct 12, 2026

Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right.

Substantial revenue from its flagship drug Casgevy should be right around the corner. Investors can expect a pivotal update on CTX310 before the end of the year.

The Motley Fool • Oct 9, 2026

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026

ZUG, Switzerland and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310®, its investigational CRISPR/Cas9 in vivo gene editing therapy targeting angiopoietin-related protein 3 (ANGPTL3), in patients with severe hypertriglyceridemia will be presented in a late-breaking oral presentation at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6 – 9, 2026. Abstract Title: CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3 for Severe Hypertriglyceridemia: Results From Phase 1b Trial Session Type: Late-Breaking Science (Oral Presentation) Session Title: LBS.05 New Frontiers in Cardiometabolic Risk Reduction Session Date and Time: Monday, November 9, 2026, 8:00 a.m.

GlobeNewsWire • Oct 8, 2026

CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $54, representing a -5.82% change from its previous close.

Zacks Investment Research • Oct 6, 2026